Technical considerations when obtaining and interpreting prostatic biopsies from men with suspicion of early prostate cancer: Part I

Chappell, Barnaby; McLoughlin, John

doi:10.1111/j.1464-410x.2005.05538.x

Cited by 9 publications

(4 citation statements)

References 104 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Proper diagnosis and treatment of prostate cancer is still a major challenge faced by oncologists and radiologists all over the world; as both PSA levels and imaging have had their limitations with respect to diagnosis, staging, and prognosis. Both conventional radiological imaging and PSA levels show high false positives during screening due to confounding effects of benign prostatic hyperplasia and prostatitis (2).…”

Section: Introductionmentioning

confidence: 99%

68Ga PSMA PET-CT: New Hope in Prostate Cancer Imaging and Therapy

Dey

2019

Bangladesh J. Nuclear Med.

View full text Add to dashboard Cite

Prostate cancer is the second most common cancer in men. Its diagnosis and management are still challenging as both PSA levels and imaging have had their limitations. Prostate specific membrane antigen (PSMA) is aprostate specific cell surface protein and has been emerging as a novel target for PET imaging of prostate cancer. 68Ga PSMA PET-CT imaging have been shown as a better imaging technology in primary prostate cancer and at the same time detecting lymph node and bone metastases even in low PSA levels. Moreover, its counterpart 177 Lu PSMA has a great prospectto be used for the treatment of castration resistantprostate cancer. Bangladesh J. Nuclear Med. 22(1): 53-57, Jan 2019

show abstract

Section: Introductionmentioning

confidence: 99%

68Ga PSMA PET-CT: New Hope in Prostate Cancer Imaging and Therapy

Dey

2019

Bangladesh J. Nuclear Med.

View full text Add to dashboard Cite

show abstract

“…Both conventional radiological imaging and PSA levels show high false positives during screening due to confounding effects of benign prostatic hyperplasia and prostatitis. [1] The advent of PET has seen the use of several radiotracers such has FDG PET, 11C-Acetate, F18-Choline, and C11- Choline for prostate cancer imaging. FDG-PET avidity in prostate cancer is minimal and variable and could be an incidental finding due to benign disease.…”

Section: Introductionmentioning

confidence: 99%

“…The significance of PSA values has to be correlated with imaging modalities since lymph node and skeletal metastases can be present without any obvious increase in PSA values or PSA levels could increase after chemotherapy without any obvious underlying disease. [1910] These problems have led to identification of more robust surface biomarkers in prostate cancer.…”

Section: Introductionmentioning

confidence: 99%

Clinical utility of gallium-68 PSMA PET/CT scan for prostate cancer

et al. 2017

View full text Add to dashboard Cite

Background:Prostate cancer is biologically and clinically a heterogeneous disease that makes imaging evaluation challenging. One of the important challenges in this cancer is to detect recurrent disease. Biochemical response using Prostate Specific Antigen (PSA) and Imaging using several PET tracers have poor sensitivity and specificity. Therefore, we analyse the role of Ga68-PSMA (Prostate Specific Membrane Antigen) imaging in prostate cancer, which is a new PET tracer.Methods:In this study, we evaluated PET scans of 262 patients with diagnosis of prostate cancer. These patients were scanned using Ga68-PSMA for either staging or response evaluation.Results:336 PSMA scans were performed. Ga68-PSMA scan resulted in the detection of extra-prostatic disease in 53.2% of cases when done at baseline before commencing any treatment. The sensitivity of Ga68-PSMA at baseline with histopathological diagnosis was 95% with 95% CI ranging from 86% to 98%. The positive predictive value was high at 98% with 95% CI ranging from 91% to 99%. In 26 (10%) patients who had surgical castration, Ga68-PSMA scan was able to detect disease progression / castration resistance in 100% of cases. The outcome of castration-resistant prostate cancer was compared with other cases where castration was not done. In those who did not undergo castration, there was a significantly better response by hormone therapy (p = 0.03) and radiotherapy (p = 0.01) on Ga68-PSMA. The sensitivity of Ga68-PSMA response with biochemical response was 66.7% with 95% CI ranging between 46 %- 82.7%. Ga68-PSMA response did not correlate with biochemical response.Conclusion:Ga68-PSMA has good sensitivity for diagnosis, staging, restaging, evaluation of therapy response and prognostication in prostate cancer.

show abstract

“…Numerous recent studies have shown that a significant number of cancers are missed with this cutoff 13 . A PSA cut-off of 4.0 ng/mL has a sensitivity of 67-80%, which implies that 20-30% of cancers are missed when only the PSA level is obtained 14 . In order to improve the sensitivity, a 2.5 ng/mL cutoff was recently recommended by the National Comprehensive Cancer Network (NCCN) in the United States.…”

Section: Detection Of Prostate Cancermentioning

confidence: 99%